Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

Tekcapital Portfolio Company Gets Funding; "On Track" For US Clearance

(Alliance News) - Tekcapital PLC on Wednesday said portfolio company Belluscura PLC is headed for ...

Alliance News 26 June, 2019 | 12:26PM
Email Form

(Alliance News) - Tekcapital PLC on Wednesday said portfolio company Belluscura PLC is headed for US regulatory clearance of its oxygen concentrator in 2019 and has received commitments for a further GBP725,000 of funding.

Shares in Tekcapital were up 6.9% at 11.22 pence shortly before midday in London.

Belluscura, in which Tekcapital holds a 22% stake, has developed X-PLOR, an oxygen concentrator capable of delivering 96% pure oxygen at all times to chronic obstructive pulmonary disease patients. The device is intended as a replacement for metal oxygen tanks and heavy devices as it ways just 1.4 kilograms.

Tekcapital said Belluscura is "on track" for US Food & Drug Administration clearance later in 2019 before a commercial launch in the first half of 2020.

"We are delighted to see that Belluscura has strengthened its balance sheet and is on track to likely receive FDA clearance later this year. The fundraise was conducted at 15 pence per share, a 50% uplift over the valuation Tekcapital listed for Belluscura in its 2018 annual accounts. The directors believe that Belluscura's new device will help to improve the quality of life and reduce treatment cost for individuals suffering from COPD," said Tekcapital Chair Clifford Gross.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Tekcapital PLC 5.65 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites